Moderna (NASDAQ:MRNA) and Tharimmune (NASDAQ:THAR) Head to Head Review

Moderna (NASDAQ:MRNA) and Tharimmune (NASDAQ:THAR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Profitability

This table compares Moderna and Tharimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moderna	-145.16%	-30.15%	-22.95%
Tharimmune	N/A	-588.45%	-264.41%

Earnings and Valuation

This table compares Moderna and Tharimmune”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94 billion	10.73	-$2.82 billion	($7.27)	-7.27
Tharimmune	N/A	N/A	-$12.20 million	($3.99)	-0.75

Tharimmune has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Moderna and Tharimmune, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5	13	2	0	1.85
Tharimmune	1	0	0	0	1.00

Moderna currently has a consensus price target of $33.87, indicating a potential downside of 35.91%. Given Moderna’s stronger consensus rating and higher probable upside, research analysts clearly believe Moderna is more favorable than Tharimmune.

Risk & Volatility

Moderna has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500.

Institutional & Insider Ownership

75.3% of Moderna shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 6.7% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Moderna beats Tharimmune on 8 of the 13 factors compared between the two stocks.

About Moderna

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.